Yuri Cho, Jin Woo Choi, Hoon Kwon, Kun Yung Kim, Byung Chan Lee, Hee Ho Chu, Dong Hyeon Lee, Han Ah Lee, Gyoung Min Kim, Jung Suk Oh, Dongho Hyun, In Joon Lee, Hyunchul Rhim, Research Committee of the Korean Liver Cancer Association
Clin Mol Hepatol 2023;29(3):521-541. Published online July 1, 2023
Transarterial chemoembolization (TACE) was introduced in 1977 with the administration of chemotherapeutic agent to gelatin sponge particles through the hepatic artery in patients with hepatocellular carcinoma (HCC) and was established as conventional TACE using Lipiodol in the 1980s. In the 2000s, drug-eluting beads were developed and applied clinically. Currently, TACE is a commonly used non-surgical treatment modality for patients with HCC who are unsuitable for curative treatment. Considering the vital role of TACE in the management of HCC, it is crucial to organize current knowledge and expert opinions regarding patient preparation, procedural techniques, and post-treatment care in TACE, which can enhance therapeutic efficacy and safety. A group of 12 experts in the fields of interventional radiology and hepatology, convened by the Research Committee of the Korean Liver Cancer Association (KLCA), has developed expert consensus-based practical recommendations in TACE. These recommendations have been endorsed by the Korean Society of Interventional Radiology and provide useful information and direction in performing TACE procedure as well as pre- and post- procedural patient care.
Citations
Citations to this article as recorded by
Epidemiological characteristics and precise prophylaxis and control of HBV-associated primary liver cancer Yuqi Feng, Letian Fang, Guangwen Cao Hepatoma Research.2025;[Epub] CrossRef
Correspondence to letter to the editor on “Transarterial radioembolization versus tyrosine kinase inhibitor in hepatocellular carcinoma with portal vein thrombosis” Moon Haeng Hur, Yoon Jun Kim Clinical and Molecular Hepatology.2025; 31(1): e93. CrossRef
A nationwide investigation on imaging follow-up after Locoregional therapy for hepatocellular carcinoma in China: Current practices and challenges Shuwei Zhou, Chenxin Song, Pei Liu, Shenghong Ju, Yuan-Cheng Wang European Journal of Radiology.2025; 186: 112057. CrossRef
The role of TACE in the era of immune-targeted therapy for hepatocellular carcinoma: a meta-analysis based on PSM Jiahao Li, Lei Xian, Xinsen Wang, Yingnan Liu, Jiarui Li Frontiers in Immunology.2025;[Epub] CrossRef
Hepatic arterial infusion chemotherapy versus transarterial chemoembolization in patients with unresectable intrahepatic cholangiocarcinoma: a multicenter retrospective cohort study Yi Zhang, Ze Zhang, Xiaoxv Yin, Anhui Xu, Yonghong Hao, Nan Jiang, Ruibing Zhou, Ketao Mu European Radiology.2025; 35(10): 6564. CrossRef
A risk prediction model for nausea and vomiting after TACE: a cross-sectional study Yali Dai, Mengting Zeng, Hong He, Miao Cai BMC Gastroenterology.2025;[Epub] CrossRef
Optimizing TACE for Hepatocellular Carcinoma: The Impact of Intra-Arterial Contrast Enhanced Ultrasound Linda Galasso, Jacopo Iaccarino, Giorgio Esposto, Gabriele Giansanti, Irene Mignini, Raffaele Borriello, Gianpaolo Vidili, Antonio Gasbarrini, Maria Elena Ainora, Maria Assunta Zocco Diagnostics.2025; 15(11): 1380. CrossRef
Optimizing Yttrium-90 Radioembolization Dosimetry for Hepatocellular Carcinoma: A Korean Perspective In Joon Lee, Hyo-Cheol Kim Korean Journal of Radiology.2025; 26(7): 688. CrossRef
Locoregional Therapies for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus Ramanpreet Singh, Mina S. Makary Journal of Gastrointestinal Cancer.2025;[Epub] CrossRef
Prognostic Role of Short-Chain Fatty Acid-Producing Gut Microbiota and Gut Microbial Dynamics in Patients with Hepatocellular Carcinoma Receiving Chemoembolization: A Prospective Study Jiwon Yang, Jihye Lim, Eun Hye Kim, Jihyun An, Danbi Lee, Han Chu Lee, Jin-Yong Jeong, Ju Hyun Shim Journal of Hepatocellular Carcinoma.2025; Volume 12: 1991. CrossRef
Fucoidan Improves Tumour Control and Liver Function in TACE for Unresectable Hepatocellular Carcinoma: A Randomised Trial Yanting Zou, Szu‐Yuan Wu, Wanqin Zhang, Wei Zhang, Xizhong Shen, Xudong Qu, Qunyan Yao Liver International.2025;[Epub] CrossRef
Embolic efficacy and safety profile of UniPearls® microspheres for hepatic artery embolization in domestic pigs Junqing Xi, Kai Liu, Min Xu, Li Dai, Zhengqiang Yang, Baosheng Ren Journal of Materials Science: Materials in Medicine.2025;[Epub] CrossRef
Nomogram for predicting post-transarterial chemoembolization survival in recurrent patients with hepatitis B virus-associated hepatocellular carcinoma Zhang-you Guo, Mu-yang Tu, Yin-shan Yang, Ling-xiang Xu, Dan-dan Fan Scientific Reports.2025;[Epub] CrossRef
Reassessing the L. reuteri/ indole-3-lactic acid pathway in TACE-related liver injury Xiang Zhang, Hui gong, Datian Chen Journal of Hepatology.2025;[Epub] CrossRef
Targeting lactic acidosis in the tumor microenvironment: Enhancing TACE efficacy in hepatocellular carcinoma Shuyi Hao, Hong Yao, Haojie Yu, Lijun Wang, Tingdong Yu, Hongping Xia, Yong Zha Liver Research.2025; 9(4): 273. CrossRef
Molecular mechanisms of TACE refractoriness: Directions for improvement of the TACE procedure Jiahao Li, Yingnan Liu, Ruipeng Zheng, Chao Qu, Jiarui Li Life Sciences.2024; 342: 122540. CrossRef
Rhein‐based Pickering emulsion for hepatocellular carcinoma: Shaping the metabolic signaling and immunoactivation in transarterial chemoembolization Xiaoliu Liang, Hui Liu, Hu Chen, Xuqi Peng, Zhenjie Li, Minglei Teng, Yisheng Peng, Jiwei Li, Linyu Ding, Jingsong Mao, Chengchao Chu, Hongwei Cheng, Gang Liu Aggregate.2024;[Epub] CrossRef
Clinical outcomes of transarterial chemoembolization in Child–Turcotte Pugh class A patients with a single small (≤3 cm) hepatocellular carcinoma Jungnam Lee, Young‐Joo Jin, Seung Kak Shin, Jung Hyun Kwon, Sang Gyune Kim, Jung Hwan Yu, Jin‐Woo Lee, Oh Sang Kwon, Soon Woo Nahm, Young Seok Kim Journal of Gastroenterology and Hepatology.2024; 39(9): 1924. CrossRef
Modular multimodal hospital-home chain physical activity rehabilitation programme (3M2H-PARP) in liver cancer: a protocol for a randomised controlled trial Haiyan Chen, Hanxiao Lu, Huimin Zhou, Bo Wu, Zhixia Dong, Shuo Zhang, Yuanlong Gu, Guangwen Zhou, Jie Xiang, Jun Yang BMJ Open.2024; 14(5): e083228. CrossRef
Recent Hepatocellular Carcinoma Managements in Korea: Focus on the Updated Guidelines in 2022 Yuri Cho, Bo Hyun Kim, Young-Suk Lim Digestive Disease Interventions.2024; 08(03): 169. CrossRef
Immune-targeted therapy with transarterial chemo(embolization) for unresectable HCC: a systematic review and meta-analysis Huipeng Fang, Qiao Ke, Shiji Wu, Qiang Tu, Lei Wang Frontiers in Immunology.2024;[Epub] CrossRef
Dexamethasone and N-acetylcysteine before transarterial chemoembolization in hepatocellular carcinoma: A Western perspective Marco Biolato, Maurizio Pompili World Journal of Gastroenterology.2024; 30(31): 3635. CrossRef
Research progress on machine algorithm prediction of liver cancer prognosis after intervention therapy Feng Guo American Journal of Cancer Research.2024; 14(9): 4580. CrossRef
Chemoembolization combined with radiofrequency ablation is the best option for the local treatment of early hepatocellular carcinoma? Hyo-Cheol Kim Clinical and Molecular Hepatology.2023; 29(4): 984. CrossRef
Combination treatment of transcatheter arterial chemoembolization, intensity-modulated radiotherapy, and sorafenib for hepatocellular carcinoma with macrovascular invasion Dan Yang, Jiaojiao Du, Weijie Nie, Chaozhi Wang, Zhufang Ma Medicine.2023; 102(45): e35713. CrossRef
Hyun Yang, Hyun Young Woo, Soon Kyu Lee, Ji Won Han, Bohyun Jang, Hee Chul Nam, Hae Lim Lee, Sung Won Lee, Do Seon Song, Myeong Jun Song, Jung Suk Oh, Ho Jong Chun, Jeong Won Jang, Angelo Lozada, Si Hyun Bae, Jong Young Choi, Seung Kew Yoon
Clin Mol Hepatol 2017;23(2):128-137. Published online May 10, 2017
Background/Aims Metronomic chemotherapy (MET) is frequently administered in comparatively low doses as a continuous chemotherapeutic agent. The aim of this study was to evaluate the feasibility and overall survival (OS) of MET compared to sorafenib for advanced hepatocellular carcinoma (HCC) patients with portal vein tumor thrombosis (PVTT).
Methods A total of 54 patients with advanced HCC and PVTT who had undergone MET were analyzed between 2005 and 2013. A total of 53 patients who had undergone sorafenib therapy were analyzed as the control group. The primary endpoint of this study was OS.
Results The median number of MET cycles was two (1-15). The OS values for the MET group and sorafenib group were 158 days (132-184) and 117 days (92-142), respectively (P=0.029). The Cox proportional-hazard model showed that a higher risk of death was correlated with higher serum alpha fetoprotein level (≥400 mg/dL, hazard ratio [HR]=1.680, P=0.014) and Child-Pugh class B (HR=1.856, P=0.008).
Conclusions MET was associated with more favorable outcomes in terms of overall survival than was sorafenib in patients with advanced HCC with PVTT, especially in patients with poor liver function. Therefore, MET can be considered as a treatment option in patients with advanced HCC with PVTT and poor liver function.
Citations
Citations to this article as recorded by
Optimal candidates and surrogate endpoints for HAIC versus Sorafenib in hepatocellular carcinoma: an updated systematic review and meta-analysis Tengfei Si, Qing Shao, Wayel Jassem, Yun Ma, Nigel Heaton International Journal of Surgery.2025; 111(1): 1203. CrossRef
The deubiquitinating enzyme ATXN3 promotes hepatocellular carcinoma progression by stabilizing TAZ Yuanhao Peng, Hui Nie, Kuo Kang, Xuanxuan Li, Yongguang Tao, Yangying Zhou Cancer Gene Therapy.2025; 32(1): 136. CrossRef
Efficacy of hepatic arterial infusion chemotherapy and its combination strategies for advanced hepatocellular carcinoma: A network meta-analysis Shun-An Zhou, Qing-Mei Zhou, Lei Wu, Zhi-Hong Chen, Fan Wu, Zhen-Rong Chen, Lian-Qun Xu, Bi-Ling Gan, Hao-Sheng Jin, Ning Shi World Journal of Gastrointestinal Oncology.2024; 16(8): 3672. CrossRef
Efficacy and Safety of Metronomic Capecitabine in Hepatocellular Carcinoma: A Systematic Review and Meta-analysis Nandini Gupta, Neelkant Verma, Bhoomika Patel Journal of Gastrointestinal Cancer.2024; 55(4): 1485. CrossRef
Clinical significance of exosomal noncoding RNAs in hepatocellular carcinoma: a narrative review Jae Sung Yoo, Min Kyu Kang Journal of Yeungnam Medical Science.2024; 42: 4. CrossRef
Hepatic arterial infusion chemotherapy versus sorafenib for advanced hepatocellular carcinoma with portal vein tumor thrombus: An updated meta-analysis and systematic review Wei Zhang, Deliang Ouyang, Zhangkan Huang, Xu Che Frontiers in Oncology.2023;[Epub] CrossRef
Management of hepatocellular carcinoma patients with portal vein tumor thrombosis: A narrative review Zi-Wen Tao, Bao-Quan Cheng, Tao Zhou, Yan-Jing Gao Hepatobiliary & Pancreatic Diseases International.2022; 21(2): 134. CrossRef
A novel chemotherapy strategy for advanced hepatocellular carcinoma: a multicenter retrospective study Juxian Sun, Chang Liu, Jie Shi, Nanya Wang, Dafeng Jiang, Feifei Mao, Jingwen Gu, Liping Zhou, Li Shen, Wan Yee Lau, Shuqun Cheng Chinese Medical Journal.2022; 135(19): 2338. CrossRef
Patterns and Outcomes in Hepatocellular Carcinoma Patients with Portal Vein Invasion: A Multicenter Prospective Cohort Study Dong Hyun Sinn, Hye Won Lee, Yong-Han Paik, Do Young Kim, Yoon Jun Kim, Kang Mo Kim, Si Hyun Bae, Ji Hoon Kim, Yeon Seok Seo, Jae Young Jang, Byoung Kuk Jang, Hyung Joon Yim, Hyung Joon Kim, Byung Seok Lee, Bo Hyun Kim, In Hee Kim, Eun-Young Cho, Jung Il Digestive Diseases and Sciences.2021; 66(1): 315. CrossRef
Survival in untreated hepatocellular carcinoma: A national cohort study Young Ae Kim, Danbee Kang, Hyeyoung Moon, Donghyun Sinn, Minwoong Kang, Sang Myung Woo, Yoon Jung Chang, Boram Park, Sun-Young Kong, Eliseo Guallar, Soo-Yong Shin, Geunyeon Gwak, Joung Hwan Back, Eun Sook Lee, Juhee Cho, Gianfranco D. Alpini PLOS ONE.2021; 16(2): e0246143. CrossRef
Capecitabine Treatment: A Safe and Effective Therapy in the Field of Oncology Linda Beenet Clinical Colorectal Cancer.2021; 20(3): e194. CrossRef
Efficacy and tolerability of Sorafenib plus metronomic chemotherapy S-1 for advanced hepatocellular carcinoma in preclinical and clinical assessments Hiroyuki Suzuki, Hideki Iwamoto, Masahito Nakano, Toru Nakamura, Atsutaka Masuda, Takahiko Sakaue, Toshimitsu Tanaka, Dan Nakano, Ryoko Kuromatsu, Takashi Niizeki, Shusuke Okamura, Shigeo Shimose, Tomotake Shirono, Yu Noda, Naoki Kamachi, Hirohisa Yano, A Translational Oncology.2021; 14(11): 101201. CrossRef
The Role of Hepatic Arterial Infusion Chemotherapy in the Treatment of Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis Shengzhou Li, Jiaxuan Xu, Hongya Zhang, Jiaze Hong, Yuexiu Si, Tong Yang, Yujing He, Derry Minyao Ng, Dingcheng Zheng Chemotherapy.2021; 66(4): 124. CrossRef
Systematic review of hepatic arterial infusion chemotherapy versus sorafenib in patients with hepatocellular carcinoma with portal vein tumor thrombosis Miao Liu, Junyi Shi, Tong Mou, Yang Wang, Zhongjun Wu, Ai Shen Journal of Gastroenterology and Hepatology.2020; 35(8): 1277. CrossRef
Diffusion-Weighted Magnetic Resonance Imaging in Hepatocellular Carcinoma as a Predictor of a Response to Cisplatin-Based Hepatic Arterial Infusion Chemotherapy Pil Soo Sung, Moon Hyung Choi, Hyun Yang, Soon Kyu Lee, Ho Jong Chun, Jeong Won Jang, Jong Young Choi, Seung Kew Yoon, Joon-Il Choi, Young Joon Lee, Si Hyun Bae Frontiers in Oncology.2020;[Epub] CrossRef
ASPP2 enhances chemotherapeutic sensitivity through the down-regulation of XIAP expression in a p53 independent manner in hepatocellular carcinoma Tongwang Yang, Yuxue Gao, Daojie Liu, Yang Wang, Jing Wu, Xiaoni Liu, Ying Shi, Dexi Chen Biochemical and Biophysical Research Communications.2019; 508(3): 769. CrossRef
Selective embolization with magnetized microbeads using magnetic resonance navigation in a controlled‐flow liver model François Michaud, Ning Li, Rosalie Plantefève, Zeynab Nosrati, Charles Tremblay, Katayoun Saatchi, Gerald Moran, Alexandre Bigot, Urs O. Häfeli, Samuel Kadoury, An Tang, Pierre Perreault, Sylvain Martel, Gilles Soulez Medical Physics.2019; 46(2): 789. CrossRef
Metronomic Chemotherapy: A Systematic Review of the Literature and Clinical Experience Cem Simsek, Ece Esin, Suayib Yalcin Journal of Oncology.2019; 2019: 1. CrossRef
Sorafenib versus hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma: a systematic review and meta-analysis Bo-wen Zhuang, Wei Li, Xiao-hua Xie, Hang-tong Hu, Ming-de Lu, Xiao-yan Xie Japanese Journal of Clinical Oncology.2019; 49(9): 845. CrossRef
Sorafenib-loaded hydroxyethyl starch-TG100-115 micelles for the treatment of liver cancer based on synergistic treatment Guofei Li, Limei Zhao Drug Delivery.2019; 26(1): 756. CrossRef
Treatment of hepatocellular carcinoma in patients with portal vein tumor thrombosis: Beyond the known frontiers Lucia Cerrito, Brigida Eleonora Annicchiarico, Roberto Iezzi, Antonio Gasbarrini, Maurizio Pompili, Francesca Romana Ponziani World Journal of Gastroenterology.2019; 25(31): 4360. CrossRef
Comparison of clinical outcomes between sorafenib and hepatic artery infusion chemotherapy in advanced hepatocellular carcinoma Min Kyu Kang, Jung Gil Park, Heon Ju Lee Medicine.2018; 97(17): e0611. CrossRef
Randomized, prospective, comparative study on the effects and safety of sorafenib vs. hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma with portal vein tumor thrombosis Jong Hwan Choi, Woo Jin Chung, Si Hyun Bae, Do Seon Song, Myeong Jun Song, Young Seok Kim, Hyung Joon Yim, Young Kul Jung, Sang Jun Suh, Jun Yong Park, Do Young Kim, Seung Up Kim, Sung Bum Cho Cancer Chemotherapy and Pharmacology.2018; 82(3): 469. CrossRef
Rationale for the use of metronomic chemotherapy in gastrointestinal cancer Roberto Filippi, Pasquale Lombardi, Ilaria Depetris, Elisabetta Fenocchio, Virginia Quarà, Giovanna Chilà, Massimo Aglietta, Francesco Leone Expert Opinion on Pharmacotherapy.2018; 19(13): 1451. CrossRef
Liver‑targeted delivery of liposome‑encapsulated curcumol using galactosylated‑stearate Wen‑Jie Li, You‑Wen Lian, Quan‑Sheng Guan, Ning Li, Wen‑Jun Liang, Wen‑Xin Liu, Yong‑Bin Huang, Yi Cheng, Hui Luo Experimental and Therapeutic Medicine.2018;[Epub] CrossRef
Can metronomic chemotherapy be an alternative to sorafenib in advanced hepatocellular carcinoma? Do Young Kim Clinical and Molecular Hepatology.2017; 23(2): 123. CrossRef
First
Prev
